ACQUISITION OF MEDICINE OUTSIDE THE CATALOG: ALGLUCOSIDASE ALPHA 50 MG - PATIENT FRANCO VALDIVIA FELIX ORLANDO

This tender concerns the acquisition of a specific medication, Alglucosidase Alpha 50 mg, for patient Franco Valdivia Felix Orlando. The procurement is being managed by the Peruvian Social Health Insurance (SEGURO SOCIAL DE SALUD - ESSALUD), a key public health institution in Peru. The contracting entity is ESSALUD, and the procurement process is taking place in the Lima department. The tender is identified by the reference number LP-CLASICO-531-2015-ESSALUD-RAR-1. The method of contracting is a Public Tender (Licitación Pública), indicating a competitive bidding process open to eligible suppliers. The requirement for a medication outside the standard catalog suggests a specialized or urgent need for this particular pharmaceutical product. ESSALUD is seeking to ensure the availability of this critical treatment for the named patient. Interested parties with the capability to supply Alglucosidase Alpha 50 mg should review the tender documents for detailed specifications, eligibility criteria, submission deadlines, and evaluation procedures. This process underscores ESSALUD's commitment to providing necessary medical treatments to its beneficiaries, even for non-standard pharmaceutical requirements.

This is a supplies contract in the governance and public administration sector. Located in Peru, Latin America, this opportunity is open to firms and consortiums, with an estimated budget of PEN 433,724.

Published through Peru SEACE, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the governance and public administration sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.